RJX Technology Drug Development
Reven’s current priorities are researching and developing cardiovascular, wound care and oncology therapies. These conditions represent large healthcare segments and often involve a substantial reduction in patient quality of life.
Reven’s vision includes proving the capacity of the RJX technology platform to overcome significant health challenges resulting in paradigm-shifting outcomes. Beyond the core modalities currently being researched, Reven intends to pursue drug development research for pain management, auto-immune disorders, metabolic disorders, PTSD, Alzheimer’s, Dementia, and more.
For the full list of our RJX drug products in the pipeline, browse below.
Join the many Clinical Research Organizations, Partners and Affiliates working with us to ignite therapeutic Impact.